Adicet Bio, Inc. is a clinical stage biotechnology company. Co. is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). We show 23 historical shares outstanding datapoints in our ACET shares outstanding history coverage, used to compute ACET market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACET market cap history over the course of time is important for investors
interested in comparing ACET's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACET versus a peer is one thing; comparing
ACET market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACET can fluctuate over the course of history.
With this page we aim to empower investors researching ACET by allowing them to research the ACET market cap history. |
Free ACET Email Alerts:
Video: The Importance of Market Cap
